This
page
is
part
of
the
Continuous
Integration
Build
of
FHIR
Specification
(v5.0.0:
R5
-
STU
).
This
is
the
current
published
version
in
it's
permanent
home
(it
will
always
(will
be
available
incorrect/inconsistent
at
this
URL).
For
a
full
list
of
available
versions,
see
times).
See
the
Directory
of
published
versions
.
Page
versions:
R5
R4B
R4
R3
Responsible
Owner:
Clinical
Genomics
Work
Group
|
Standards Status : Trial Use |
The era of precision medicine-- an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person-- is upon us.
Precision
medicine
is
fueled
by
the
amazing
technological
advancements
in
genomics,
making
it
possible
(and
feasible)
to
undertake
broad
genetic
testing
on
an
individual
in
a
clinically
useful
timeframe.
Whereas
not
so
long
ago
genomics
was
primarily
of
concern
to
bioinformaticists
interacting
with
such
artifacts
as
alignment
(e.g.
(e.g.,
BAM,
CRAM)
and
variant
calling
(e.g.
(e.g.,
VCF)
data
files,
we
are
now
seeing
tremendous
interest
across
the
clinical
community
for
integrating
genomics
findings
and
recommendations
into
the
EHR
and
into
the
care
process.
To
that
end,
the
HL7
Clinical
Genomics
Work
Group
is
developing
a
set
of
standards
for
reporting
structured
genomic
data
using
FHIR.
An individual's genetic data set is large and complex, and therefore requires systems that can manage the size and make sense of the complexity. Unfortunately, due to a lack of widely adopted standards, these systems are often incompatible. A standards-based approach to data exchange that could be adopted to integrate both genetic data and clinical information systems will be crucial to accelerating the integration of precision medicine and to make sense of genetic testing results in a complete clinical context.
The
Clinical
Genomics
Work
Group
supports
the
HL7
mission
to
create
and
promote
its
standards
by
enabling
the
semantically
meaningful
exchange
of
data
between
parties
interested
in
clinical,
personal,
and
population
genomic
information
and
family
health
history,
which
are
required
to
support
precision
medicine.
The
committee's
work
products
include:
Genomics
Reporting
Implementation
Guide:
Standardizes
the
reporting
of
genomic
variants,
haplotypes,
genotypes,
variant
annotations,
and
more.
MolecularSequence
MolecularDefinition
Resource:
A
The
MolecularDefinition
resource
representing
a
represents
molecular
entities
(e.g.,
nucleotide
or
protein
polymer.
This
sequences)
for
both
clinical
and
non-clinical
use
cases,
including
translational
research.
The
resource
was
created
prior
to
is
definitional,
in
that
it
focuses
on
discrete,
computable,
and
semantically
expressive
data
structures
that
reflect
the
development
of
genomic
domain.
Because
the
Genomics
Reporting
resource
focuses
on
the
molecular
entities
rather
than
specimen
source
or
annotated
knowledge,
it
supports
both
patient/participant-specific
use
cases
and
population-based
data,
and
both
human
and
non-human
data.
Molecular
Definition
Implementation
Guide.
Because
Guide
for
Molecular
Data
Types
is
an
emerging
product
that
includes
profiles
for
structured
representation
of
this,
there
are
currently
redundancies
between
the
two
which
need
to
be
reconciled
(e.g.,
variants),
fundamental
concepts
such
as
Sequence
,
Allele
,
and
MolecularSequence
will
be
refactored
Variation
,
Haplotype
,
and
Genotype
.
This
guide
is
work
in
the
future
to
reduce
this
redundancy
as
much
as
possible.
Wherever
possible,
defer
to
the
Genomics
Reporting
IG
progress
and
will
evolve
to
guide
your
approach
reporting
genomics
lab
results.
represent
additional
concepts.
GenomicStudy Resource: A resource that aims at delineating relevant information of a genomic study. A genomic study might comprise one or more analyses, each serving a specific purpose. These analyses may vary in method (e.g., karyotyping, CNV, or SNV detection), performer, software, devices used, or regions targeted.
Uses
of
these
FHIR
artifacts
and
other
genomic
use
cases
can
be
found
here